Pollom RK, et al. - A comparative exploration was performed of the efficacy and safety of Basaglar [insulin glargine 100 units/mL; LY insulin glargine (LY IGlar)] to Lantus [insulin glargine 100 units/mL; SA insulin glargine (SA IGlar)] in older (≥ 65 years) or younger (< 65 years) patients with type 2 diabetes (T2D). Findings disclosed that patients ≥ 65 years had a significantly longer duration of diabetes, lower baseline A1c and body weight, and body mass index vs patients < 65 years. Nonetheless, it was deduced that similar efficacy and safety were demonstrated by LY IGlar and SA IGlar in patients with T2D who were ≥ 65 years and in those aged < 65 years.